status of usage of olanzapine in patients with malignancies at our hospital

status of usage of olanzapine in patients with malignancies at our hospital - status of usage of olanzapine in patients with malignancies at our hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044105

Enrollment

Registered

2021-05-05

Start date

2020-09-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant tumor disease who received a prescription for olanzapine at Kanto Central Hospital of the Public School Mutual Aid Association between 2008, when olanzapine was launched, and May 2020.

Exclusion criteria

Exclusion criteria: Those who were prescribed the drug to treat comorbidities unrelated to malignancy. Those who refused to participate in the study by opting out.

Design outcomes

Primary

Measure	Time frame
Response rate of symptom relief with olanzapine for each symptom	—

Secondary

Measure	Time frame
Duration of prescription, reason for stopping prescription, number of days alive or days to end of treatment after starting, side effects	—

Countries

Japan

Contacts

Public ContactNatsuki Nakagawa

Kanto Central Hospital of the Mutual Aid Association School of Teachers Respiratory Medicine

nnakagawautmedsle@yahoo.co.jp03-3429-1171

Outcome results